HUYABIO International
Zhijun (ZJ) Wang has extensive experience in research and data management, holding various titles from Director of Research to SVP Research at HUYABIO International. Prior to this, at CalciMedica, Inc., ZJ was a Senior Scientist involved in designing and synthesizing inhibitors for the treatment of inflammatory and autoimmune diseases. ZJ has also made significant contributions at Kemia, Inc., advancing a clinical candidate into phase II trials. With a Ph.D. in Pharmaceutical Chemistry from Heidelberg University and previous postdoctoral fellowships at The Scripps Research Institute and ETH Zurich, ZJ brings a strong academic background to their professional career.
HUYABIO International
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.